Video & Transcript : 'pharmaceutical compounding' :
Page 26 of 172
MN
Transcript Highlights:
- see if we could shift some of the elements of healthcare delivery that have enormous profits, pharmaceutical
- manufacturers, pharmaceutical distributors, private health insurance plans, to those who need help.
- see if we could shift some of the elements of healthcare delivery that have enormous profits, pharmaceutical
- manufacturers, pharmaceutical distributors, private health insurance plans, to those who need help.
- </c> manufacturers, pharmaceutical manufacturers, pharmaceutical distributors,<00:30:48.480><c> private
HI
Hawaii 2025 Regular Session
AGR Public Hearing - Wed Feb 12, 2025 @ 9:30 AM HST
Agriculture & Food Systems
Transcript Highlights:
- Legislative bills are fast-tracked to appropriate funds to respond, pharmaceutical drugs such as historical
- to</c><01:01:13.760><c> respond</c> appropriate funds to respond appropriate funds to respond pharmaceutical
- 14.880><c> drugs</c><01:01:15.200><c> such</c><01:01:15.359><c> as</c><01:01:15.480><c> a</c> pharmaceutical
- drugs such as a pharmaceutical drugs such as a historical<01:01:16.359><c> tlu</c><01:01:17.359><c>
- Octopus farms would pose a compound threat to Kona crabs and other marine populations.
WA
Transcript Highlights:
- intentional preventative approach to men and boys, particularly where social and economic conditions compound
- This is compounded by problems with hospital policies and PBMs who encourage, by the use of their formularies
- I'm the state representative for the Pharmaceutical Industry Labor Management Association.
- you amend the language to clearly establish the repower definition and ensure that that includes compounded
Keywords:
postsecondary education, homelessness, foster youth, education access, support programs, commission, gender equity, boys, men, advocacy, state policy, special education, parental rights, educational access, evaluation reports, disability services, behavioral health, emergency services, health insurance, provider access
MO
Missouri 2026 Regular Session
Higher Education and Workforce Development Mar 3rd, 2026
Higher Education and Workforce Development
NM
Transcript Highlights:
- This is for pharmaceutical breakthroughs, battery breakthroughs, chemistry breakthroughs, the likes of
- intellectual property generated from the quantum computers, whether it's sort of like a new formula for pharmaceutical
- And so this is not a long-term application like maybe pharmaceutical breakthroughs is.
Summary:
The committee first discussed the state budget and employee compensation, focusing on the 1% pay increase proposal and the broader cost of state employee raises and benefits. Members noted that over the past several years the state has invested heavily in payroll, pension contributions, pay studies, and band realignments, and several senators argued that the 80/20 health insurance change and other benefit improvements amount to significant compensation increases even without an additional raise. Others cautioned that recurring revenue is limited, that recent revenue collections were weaker than expected, and that the state should be careful about committing to ongoing costs given possible economic slowdown, federal uncertainty, drought, wildfire risk, and the possibility of future budget pressure.
The committee then heard extensive testimony on SB 177, a major economic development proposal centered on quantum computing, advanced energy, robotics, synthetic biology, and related technologies. Supporters described the bill as a large strategic investment intended to leverage New Mexico’s national laboratories, universities, and existing quantum workforce to attract companies, create high-wage jobs, and diversify the economy. Testimony emphasized that much of the quantum workforce would be skilled trades and technicians rather than Ph.D.-level researchers, and members asked detailed questions about whether the state would receive long-term returns, how intellectual property and clawbacks would be handled, and whether the package included recurring costs. Witnesses also explained the bill’s trade association and workforce-development components, and several senators raised concerns about energy use, water use, guardrails, and ensuring the state does not subsidize outside interests without benefits returning to New Mexico.
After debate, the committee moved to table SB 177 indefinitely, with members noting that the funding and structure were already incorporated into House Bill 2. The motion passed on an 8-0 vote, with several members excused. The meeting then adjourned.
OK
Oklahoma 2026 Regular Session
Children, Youth and Family Services REVISED: Links added Feb 4th, 2026 at 03:00 pm
Children, Youth and Family Services
Transcript Highlights:
- Initially, I was concerned about what if someone wants to buy a cheaper price on a pharmacy or pharmaceutical
- You explained that pharmaceutical items are not part of SNAP, so that was one thing.
Keywords:
immigration, public assistance, legal status, food assistance, state benefits, family resource center, community support, employment services, kinship families, social connections, child care, criminal history, background checks, child safety, licensing, Oklahoma laws, advisory committees, daycare, licensed child care facility, child care subsidy
ND
North Dakota 2025-2026 Regular Session
House Human Services Apr 15th, 2025 at 03:30 pm
Human Services
Transcript Highlights:
- contract pharmacies, health insurers, and a professional association representing innovative pharmaceutical
- you have in front of you, but also adding a professional association representing innovative pharmaceutical
Summary:
The committee met with a quorum and took up the final bill on its agenda, Senate Bill 2370, which had been converted into a 340B drug transparency measure tied to insulin and broader prescription drug pricing issues. Representative Hendrix outlined the latest bill draft, explaining that it would require reporting by covered entities, contract pharmacies, federally qualified health centers, drug manufacturers, pharmacy benefit managers, and health insurers, with confidentiality protections, civil penalties, and staggered effective dates. He also noted unresolved questions about the scope of required reporting, possible overlap with federal reporting, and whether the Insurance Department would need a consultant to analyze the data.
Representative Dobervich then proposed an alternative amendment that would replace the bill language with a Legislative Management study on 340B transparency reporting during the 2025-26 interim. Her proposal would remove the detailed reporting mandates and instead direct a study of what information should be collected, how it should be used, who should receive it, staffing or contracted support needs, and stakeholder input from hospitals, pharmacies, FQHCs, rural health, state agencies, insurers, and manufacturers. Members discussed germaneness, the late-stage nature of the changes, and whether the issue had been adequately heard, while the Insurance Department testified that it had not previously studied 340B-specific data but supported transparency and could see value in either a study or reporting approach.
The committee first adopted the Hendrix amendment by a vote of 8-5, then voted on a do not pass motion on the amended bill, which passed 7-6. Representative Frelich was selected to carry the bill. The chair then adjourned the committee for the last time and reminded members about the committee dinner.
AL
Alabama 2025 Regular Session
Alabama Senate Finance and Taxation Education Committee Mar 5th, 2025
Finance and Taxation Education
NH
New Hampshire 2026 Regular Session
House Executive Departments and Administration (01/15/2026)
Executive Departments and Administration
Transcript Highlights:
- And are we not advertising on behalf of a pharmaceutical company?
- And are we not advertising on behalf of a pharmaceutical company?
- And are we not advertising on behalf of a pharmaceutical company?
- And are we not advertising on behalf of a pharmaceutical company?
- Are behalf of a pharmaceutical company?
NH
New Hampshire 2026 Regular Session
House Commerce and Consumer Affairs (04/22/2026)
Commerce and Consumer Affairs
Transcript Highlights:
- The insurance companies, pharmaceutical companies all treat her as my primary care physician.
- The insurance companies, pharmaceutical companies all treat her as my primary care physician.
- The insurance companies, pharmaceutical companies all treat her as my primary care physician.
- The insurance companies, pharmaceutical companies all treat her as my primary care physician.
- <02:05:24.680><c> benefit</c><02:05:25.080><c> manager</c> pharmaceutical benefit manager pharmaceutical
AL
Alabama 2026 Regular Session
Alabama House Mobile County Legislation Committee Jan 28th, 2026
Mobile County Legislation
Transcript Highlights:
- We also participate in pharmaceutical and clinical trials. newsletter in your packet.
- We also participate in pharmaceutical<00:21:23.840><c> and</c><00:21:24.080><c> clinical</c><00:21:24.480
- </c><00:21:25.679><c> So</c> pharmaceutical and clinical trials.
- So pharmaceutical and clinical trials.
CA
California 2025-2026 Regular Session
Assembly Select Committee on Asia/California Trade and Investment Aug 20th, 2025
Transcript Highlights:
- there's more and more being done where I think California is leading in terms of biotech and pharmaceuticals
- There's obviously, in the pharmaceutical industry... ...tech, pharmaceuticals.
- There's obviously, in the pharmaceutical industry in particular, there could be a lot of synthesis between
Summary:
The Assembly Select Committee on Asia, California, Trade and Investment held its first informational hearing to examine California’s economic ties with Asia, the effects of federal tariffs, and ways the state can strengthen trade, investment, tourism, and subnational diplomacy. Chair Jessica Caloza opened by emphasizing California’s role as the world’s fourth-largest economy and a major exporter to Asia, and several members and guests highlighted the importance of AAPI communities, sister-city relationships, and coordinated state outreach. Lieutenant Governor Eleni Kounalakis described California’s trade missions, APEC hosting, and ongoing climate and trade partnerships, while Japan’s deputy consul general underscored Japan’s role as a major investor and trading partner and encouraged continued engagement.
The first panel, featuring leaders from the Los Angeles County Economic Development Corporation/World Trade Center Los Angeles, the San Francisco Chamber of Commerce, and Visit California, focused on trade, tourism, and investment trends. Witnesses said tariffs and federal uncertainty are disrupting logistics, manufacturing, business travel, higher education, and tourism, with particular concern about port activity, international student declines, and reduced visitation from Asia. They urged California to remain “open for business,” invest in promotion and infrastructure, and use trade missions, MOUs, and sister-city ties to maintain relationships and attract investment.
The second panel, with economist Kyle Handley and trade expert Glenn Fukushima, focused on the mechanics and consequences of tariffs. Both said tariffs function as taxes on importers and consumers, raise costs for businesses, and create uncertainty that delays investment, hiring, and supply-chain decisions. They warned that California is especially exposed because of its ports, cross-border trade, and reliance on global supply chains, and said new federal vessel fees and shifting trade routes could divert commerce away from California. They argued that the long-term damage includes lost growth and reduced U.S. credibility, and recommended that California “tariff-proof” its economy through faster ports, better infrastructure, export assistance, and reduced permitting barriers.
In the final panel, representatives from the San Diego Regional Chamber of Commerce, Asian Business Association California, and the Small Business Development Center emphasized future opportunities and the needs of small businesses. They said California should deepen ties with Asia through conventions, tourism, and sector-specific partnerships in life sciences, clean tech, semiconductors, hospitality, and small business trade. The witnesses stressed that small and minority-owned businesses need more access to trade missions, capital, technical assistance, and state support, and that California’s economic strength depends on coordinated efforts across regions and industries.
MN
Minnesota 2025-2026 Regular Session
Minnesota House passes HF2403, the commerce policy bill 4/29/25
Minnesota House Floor Meeting
Transcript Highlights:
- to acquire more health insurance companies, but to acquire actual providers and pharmacies and pharmaceutical
- It is also the largest owner of physicians' practices and owns one of the big three pharmaceutical benefit
- to acquire more health insurance companies, but to acquire actual providers and pharmacies and pharmaceutical
- It is also the largest owner of physicians' practices and owns one of the big three pharmaceutical benefit
OK
Transcript Highlights:
- reversing their previous stance and saying that these Type of procedures, including the medical or pharmaceutical
- facilitate and promote refer or perform these types of procedures, whether they're surgical or pharmaceutical
Keywords:
2030 census, complete count committee, census outreach, decennial census, enumeration, population count, hard-to-count populations, hard-to-enumerate areas, State Data Center, Oklahoma Census, multilingual campaign, public outreach, school-based outreach, community organizations, minority groups, ethnic minorities, language minorities, self-response rate, census awareness, federal census
CO
Colorado 2026 Regular Session
Colorado Senate 2026 Legislative Day 022 Feb 5th, 2026
Colorado Senate Floor Meeting
Transcript Highlights:
- I am unwaveringly supportive of health care providers, facilities, pharmaceutical companies, because
- pharmaceutical companies, they get a bad rap sometimes, but they do amazing work in keeping us healthy
- There are a huge number of benefits that pharmaceutical companies bring to our society.
- companies, they get a bad pharmaceutical companies, they get a bad rap<01:46:31.199><c> sometimes,</
- companies bring to that pharmaceutical companies bring to our<01:47:05.840><c> society.
DE
Delaware 2025-2026 Regular Session
House of Representatives Legislative Session - Session 2 - 41st Legislative Day Jun 25th, 2026
Delaware House Floor Meeting
Transcript Highlights:
- But I sat there and thought about my prior life where we were contracting for pharmaceuticals within
- But the federal government cracked down years ago on how much a pharmaceutical rep could leave with a
- They contract the pharmaceutical manufacturers and have very large—” “Pharmaceutical manufacturers and
- It is why sometimes when you go to a retail pharmacy, you cannot get that brand of pharmaceutical filled
- “You cannot get that brand of pharmaceutical filled immediately because it’s going out of where they
Summary:
The House convened with Girl State participants presiding for part of the session, including introductions of the student leadership and a unanimous voice vote passing House Concurrent Resolution 152 honoring the young women participating in Delaware Girl State. The chamber also welcomed congressional interns and other guests, accepted the prior day’s minutes, and observed a moment of silence for Nathan Cynix and Kara Feeley before prayer and the Pledge of Allegiance.
A major portion of the meeting was devoted to tributes for Representative Ron Gray, who was recognized for his 14 years of service and his work on issues such as bond bills, dredging, bike paths, small business, constituent service, and agriculture-related funding. Multiple members from both parties praised his humor, honesty, mentorship, and dedication to the House and his district. Gray responded with extended remarks reflecting on his family legacy, legislative service, and appreciation for colleagues and staff, and the chamber later sang “Take Me Out to the Ball Game” at his request.
The House then received communications, including Senate messages returning several bills and informing the chamber of Senate passage of additional measures. Members were also told that the FY27 bond bill, House Bill 500, had been placed on desks as a gift for review. The House read in Consent Agenda S, which included House Bill 476, House Joint Resolution 13, Senate Substitute 1 for Senate Bill 168, Senate Bill 297, Senate Substitute 1 for Senate Bill 319, and Senate Joint Resolution 21, and began a roll call vote on the consent agenda.
HI
Transcript Highlights:
- I'm with the Pharmaceutical Care Management Association.
- So, we have offered an amendment by our comments that would remove the pharmaceutical elements out of
- 10:38.560><c> would</c><00:10:38.800><c> remove</c><00:10:39.279><c> the</c><00:10:39.600><c> pharmaceutical
- </c> that would remove the pharmaceutical that would remove the pharmaceutical elements<00:10:40.720>
Summary:
The committee heard testimony on several health-related bills. HB 72 on pharmacy drew only support, with testimony from the University of Hawaiʻi system, the Board of Pharmacy, pharmacists, and others; no questions were raised. HB 237 on peer support programs also received broad support from the Department of Health, DHS, early learning officials, families, and advocates, with testimony emphasizing the value of peer-to-peer mentoring and support for parents, youth, and people with disabilities; no opposition or questions were noted.
HB 250, the prior authorization bill, generated the most discussion. SHPDA supported a revised version focused on reporting prior authorization practices and creating a nonbinding working group to develop automation standards, while PCMA, HMSA, Kaiser Permanente, and others raised concerns about duplicative pharmacy requirements, unintended consequences, and alignment with federal timelines and reporting. Several medical groups and individual patients supported the measure, describing delays and burdens caused by prior authorization. A committee member asked whether the bill’s working group differed from a similar group in Senate Bill 1449, and the witness said it was intended to be the same.
HB 303 on health care preceptors was supported by the Department of Health, University of Hawaiʻi, nursing and health care organizations, and the Hawaii Pharmacists Association, which asked that pharmacists’ residency programs be specifically tied to national accreditation standards. HB 341, relating to issuance of SPURS to assist the Hawaii Island Community Health Association, drew support from the health center and related groups. HB 692 on Preschool Open Doors received extensive support from early learning, education, family, labor, and community organizations; testimony stressed the shortage of child care and preschool slots, especially on Kauai, and the need to expand access for families. Committee members asked about adding family child care providers and about licensing/certification barriers, and DHS said the bill was focused on current licensed child care facilities and that certification issues were a separate, broader problem. HB 700 on cognitive assessments also drew strong support, with the Department of Health, the Executive Office on Aging, disability advocates, the Alzheimer’s Association, caregivers, and others urging use of a validated cognitive assessment tool during annual wellness visits and asking that the age 65 threshold be removed; some witnesses supported keeping the data-collection portion as a pilot and emphasized early detection and reporting.
NM
New Mexico 2025 Regular Session
IC - Investments and Pensions Oversight Oct 8th, 2025
Investments & Pensions Oversight Committee
Transcript Highlights:
- COLAs can be simple or compound.
- COLA and a non-compounding COLA.
- If we look at it for a non-compounding COLA, so again a 2% non-compounding COLA, it still has a pretty
- mean when you talk about compound?
- We call it a non-compounding COLA.
CT
Connecticut 2026 Regular Session
Medical Assistance Program Oversight Council Complex Care Committee May 21st Meeting May 21st, 2026
Transcript Highlights:
- So I just have a question about the pharmaceuticals because one of the things, first of all, from the
- But the money for the 340B program has been taken over pretty much by hospitals that provide pharmaceuticals
- Have those distinctions been made in your analysis with respect to pharmaceuticals? No.
Summary:
The Complex Care Committee meeting focused first on a new Diabetes Caucus launched at the Capitol. Rep. Johnson described the caucus as a forum to educate people about type 1 and type 2 diabetes, genetic risk, early testing, pregnancy-related diabetes, and ways Medicaid policy might improve prevention and lower long-term costs. Members agreed the caucus could intersect with care management, and Carolyn Grandell of CHNCT offered to share information about current diabetes-related care management services at a future meeting.
The committee then heard a detailed presentation from Alex Rigger of the Office of Health Strategy, who is moving to the Office of Policy and Management. He reviewed Connecticut health care benchmark data, including total health care expenditures, medical spending, and market-by-market trends. He said 2023 to 2024 per-capita spending grew more than 8.5% statewide and 14% in Medicaid, with long-term care accounting for about 46% of Medicaid spending and retail pharmacy also identified as a major cost driver. Members asked about enrollment changes, dual-eligible populations, Medicare Savings Program members, 340B drug pricing, and value-based payment models. Rigger explained that his office tracks alternate payment models and quality benchmarks, but does not separately capture 340B data.
Discussion then shifted to Medicare Advantage, dual eligibles, and hospital discharge planning. Members said they want better data on how many Medicaid members are in Medicare Advantage plans and whether those plans shift costs back to Medicaid or affect access to care, especially for complex-care patients. Staff noted DSS does have some Medicare Advantage indicators and that CMS is developing encounter-data rules for states. Kathy Holt and others raised concerns about denials, nursing home stays, and the need to compare Medicaid spending for dual eligibles in Medicare Advantage versus traditional Medicare. The meeting ended with plans for follow-up data sharing, including Alex Rigger’s slides, the diabetes caucus materials, and a future discussion with DSS and other agencies; no formal votes were taken.
MN
Minnesota 2025-2026 Regular Session
Regulating Artificial Intelligence / Legislation to Stop Dangerous Deepfakes Mar 16th, 2025
Minnesota Senate Floor Meeting
Transcript Highlights:
- space, right, there's general, whether it be 5 milligram, 25 milligram, 50 milligrams of XYZ pharmaceutical
- of</c><00:26:13.960><c> XYZ</c> milligram 50 milligrams of XYZ milligram 50 milligrams of XYZ pharmaceutical
- 16.360><c> is</c><00:26:16.559><c> more</c><00:26:17.240><c> general</c><00:26:18.240><c> what</c> pharmaceutical
- that is more general what pharmaceutical that is more general what if<00:26:19.600><c> as</c><00:26: